Clinical Trials in Austin

Showing 1481-1500 of 15,205 trials

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm

Crinetics Pharmaceuticals Inc.150 participantsStarted Nov 2025

Duarte, California, United States • Newport Beach, California, United States • Orange, California, United States +18 more locations

TERMINATEDPhase 3< 1 mile

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

Migraine

Eli Lilly and Company851 participantsStarted Jun 2020

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Phoenix, Arizona, United States +149 more locations

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Find Trials by Condition in Austin

A Just-in-Time Adaptive Intervention for Child and Family Mental Health

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

CARE: Cancer Risk Perception and Women of Color

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision